An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)
Publication/Presentation Date
4-2017
Volume
28
Issue
2
First Page
48
Last Page
49
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article
COinS